ObsEva drops linzagolix, focuses on prospects for preterm labor, IVF
ObsEva plans to drop linzagolix, its leading candidate for the treatment of uterine fibroids, following concerns raised by the FDA.
ObsEva announced this week its plans to drop linzagolix as treatment for uterine fibroids, following the US Food and Drug Administration’s (FDA) concerns regarding deficiencies in the company’s New Drug Application for linzagolix. The company will undergo corporate restructuring to target its efforts on the reevaluation of its development and commercialization strategies.1
The company has been in close contact with the FDA and plans to submit additional data to address concerns within the application. In the meantime, ObsEva is unable to continue its labeling and post-market commitments and the original target action date of September 13 will be put on hold.
ObsEva also announced its decision to terminate its agreement with Kissei, from whom it licensed linzagolix in 2015. Its licensing agreement with Theramex, for the commercialization and marketing of linzagolix, will be transferred to Kissei.
These changes, ObsEva stated, will allow the company to meet its other obligations and support its other licensing agreements. Specifically, its current agreement with Organon for the development and commercialization of ebopiprant—an orally active, selective prostaglandin F2α receptor antagonist for the potential treatment of preterm labor—and its sublicense agreement with YuYuan BioScience for nolasiban—an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates for women undergoing in-vitro fertilization.2,3
For the latest news and updates to the drug and device pipeline, check Contemporary OB/GYN®’s Drug Pipeline News.
References
- ObsEva Announces Corporate Updates. ObsEva. Published July 27, 2022. Accessed July 28, 2022. https://www.obseva.com/pressrelease-detail/?pr=5112&doing_wp_cron=1659022122.6047220230102539062500
- Nolasiban (OBE001) —Assisted Reproductive Technology. ObsEva. Published June 12, 2019. Accessed July 28, 2022. https://www.obseva.com/nolasiban/
- Our Pipeline - Overview. OsEva. ObsEva. Published June 11, 2019. Accessed July 28, 2022. https://www.obseva.com/our-pipeline-overview/
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More
